P. Stella

发表

Prospective evaluation of vitamin E for hot flashes in breast cancer survivors.

P. Novotny, J. Sloan, C. Loprinzi, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The value of combined‐modality therapy in elderly patients with stage III nonsmall cell lung cancer

J. Jett, S. Mandrekar, A. Adjei, 2007, Cancer.

Smoking behavior of 226 patients with diagnosis of stage IIIA/IIIB non‐small cell lung cancer

C. Patten, J. Sloan, R. Marks, 2002, Psycho-oncology.

Lack of effect of coumarin in women with lymphedema after treatment for breast cancer.

P. Novotny, J. Sloan, C. Loprinzi, 1999, The New England journal of medicine.

Phase III evaluation of fluoxetine for treatment of hot flashes.

E. Perez, T. Rummans, P. Novotny, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102.

J. Manola, B. Ramaswamy, A. Wolff, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy

T. Ciuleanu, G. Bodoky, N. Tebbutt, 2012, Investigational New Drugs.

Prophylactic cranial irradiation in small-cell lung cancer: findings from a North Central Cancer Treatment Group Pooled Analysis.

N. Foster, A. Adjei, K. Olivier, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Pregabalin for hot flashes in women: NCCTG trial N07C1.

C. Loprinzi, K. Rowland, S. Dakhil, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The possible advantage of hyperfractionated thoracic radiotherapy in the treatment of locally advanced nonsmall cell lung carcinoma

E. Shaw, J. Sloan, E. Creagan, 1998, Cancer.

A Phase II, Open-Label, Randomized Study to Assess the Efficacy and Safety of AZD6244 (ARRY-142886) Versus Pemetrexed in Patients with Non-small Cell Lung Cancer Who Have Failed One or Two Prior Chemotherapeutic Regimens

J. Hainsworth, T. Ciuleanu, V. Tzekova, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Efficacy and safety of AZD6244 (ARRY-142886) as second/third-line treatment of patients (pts) with advanced non-small cell lung cancer (NSCLC)

J. Hainsworth, T. Ciuleanu, V. Tzekova, 2008 .

Erratum to: A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy

T. Ciuleanu, G. Bodoky, N. Tebbutt, 2012, Investigational New Drugs.

Phase 1/2 trial of temsirolimus and sorafenib in the treatment of patients with recurrent glioblastoma: North Central Cancer Treatment Group Study/Alliance N0572

J. Sarkaria, J. Buckner, B. Erickson, 2018, Cancer.

Final efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC)

M. Socinski, V. Velcheti, D. Shames, 2019, Annals of Oncology.

A randomized phase II study of gemcitabine (G) and carboplatin (C) with or without cediranib (AZD2171 [CED]) as first-line therapy in advanced non-small cell lung cancer (NSCLC).

S. Mandrekar, A. Adjei, G. Dy, 2010 .